^
    Back
    Association details:
    Biomarker:CD20 expression
    Cancer:Childhood B Acute Lymphoblastic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    bortezomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood Adv
    Title:

    Bortezomib and Rituximab in de-novo adolescent/adult CD20-positive, Ph-negative Pre B-cell acute lymphoblastic leukemia

    Published date:
    08/30/2021
    Excerpt:
    At a median follow-up of 21 months, the event-free survival and overall survival were 78.8% [95% CI - 66%- 94%] and 78.7% [95% CI - 65.8%- 94%]...The combination of bortezomib, rituximab, and a pediatric-inspired ALL regimen is active and well-tolerated in de-novo CD20-positive Ph-negative precursor B-ALL. 
    DOI:
    10.1182/bloodadvances.2020003368
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    1024 Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study

    Published date:
    11/03/2020
    Excerpt:
    After a median follow up of 18 months, event-free survival and overall survival were 81.8% and 84.7%, respectively....The combination of bortezomib, rituximab and paediatric-inspired ALL regimen is active and well tolerated in in de-novo CD20 positive Ph-negative precursor B-ALL.